Investors focused on Medical - Biomedical and Genetics stocks may have come across Exelixis (EXEL) and Techne (TECH). However, which of these two stocks is more appealing to value investors?
Exelixis, a company that specializes in cancer drugs, had a great day in the stock market on Friday. After announcing a significant decision that pleased its shareholders, investors rushed to buy its shares, causing a 5% increase in value.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) has revealed that its Board of Directors has approved the buyback of an extra $500 million of the company's common stock, which will take place before December 31, 2025. The company intends to finish its current $500 million stock repurchase program, announced in August 2024, by the second quarter of 2025, and will start the new buyback program afterward. The February 2025 program is the fourth of its kind.
Exelixis (EXEL) has the potential to deliver impressive returns due to its strong growth characteristics.
EXEL stock is rising due to the positive results of its main drug, Cabometyx, and strong advancements in its drug development pipeline. We are hopeful about the stock's future as we see potential for more growth.
Look into Exelixis' (EXEL) international revenue patterns and how these figures influence Wall Street's predictions and the future of the stock. Understanding these trends can provide insights into the company's performance and potential growth.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) has shared the final results from the phase 3 CheckMate -9ER trial, which studied CABOMETYX® (cabozantinib) combined with Opdivo® (nivolumab) against sunitinib for patients with untreated advanced renal cell carcinoma (RCC). After over five years of monitoring, the results showed that the effectiveness of CABOMETYX with Opdivo was maintained over the long term. These findings also included subgroup analyses.
No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the best features of the Zacks Premium research service.
Exelixis has reported better-than-expected earnings and sales for the fourth quarter, with its main drug, Cabometyx, continuing to perform well. The company has also confirmed its forecasts for 2025.
Exelixis announced that its net product revenues reached $515.2 million in the fourth quarter of 2024, which is a 20% rise compared to the same period in 2023. For 2025, the company expects total revenues to remain steady at between $2.15 billion and $2.25 billion, not accounting for the possible approval of cabozantinib for neuroendocrine tumors. The results of Exelixis's STELLAR-303 trial for zanzalintinib in metastatic colorectal cancer are anticipated in the second half of 2025, but predicting the outcome is difficult.